Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| GlaxoSmithKline | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to determine the efficacy of 6 months of 4 g/day oral Lovaza® on endothelial-dependent and heat-induced vasodilation in type 2 diabetics with neuropathy and elevated triglyceride levels. Omega-3 fatty acids appear to exert beneficial effects on vascular function that are independent of the changes in serum triglycerides. The efficacy will be compared with a placebo given at the same duration. Efficacy of the drug will be evaluated after 3 and 6 months of treatment. This timeline should be adequate for evaluation of the primary neurophysiological endpoints. Previously, the investigators have demonstrated that it is feasible to pharmacologically alter nerve fiber density in as little as 18 weeks and that this correlates with subjective and objective measures of neurovascular function. The investigators are predicting an enhancement of post-ischemic hyperemia of the foot dorsum, where the dilative mechanism is primarily endothelium-dependent and a similar improvement in heat-induced hyperemia.
This pilot study is a within-subject repeated measures design. This study will compare the neurophysiological and vascular responses to placebo and treatment with Lovaza® (omega-3-acid ethyl esters, Reliant Pharmaceuticals, Inc.) in subjects with type 2 diabetes, neuropathy, and dyslipidemia.
Lovaza's potential mechanism of action is the inhibition of acyl Coenzyme A:1, 2-diacylglycerol acyltransferase and increased peroxisomal β-oxidation in the liver.
Subjects will be recruited and a baseline of physiological, neurological and hematological profile established for each patient. Forty-four subjects (20 in the active arm, 20 in the placebo arm, and 2 replacements for each arm) will receive 4 g/day Lovaza® tablets or placebo for a period of 6 months. All subjects will receive a physical and neurological exam as well as neurovascular function testing. This includes nerve conduction studies, quantitative sensory testing, quantitative autonomic testing, and skin blood flow testing, which includes, ischemia reperfusion. Lab tests include an insulin resistance profile, hepatic and renal function profiles, lipid profile, C-reactive protein, thyroid stimulating hormone, and fatty acids. Other tests include inflammatory markers such as adiponectin and tumor necrosis factor-α. The study is powered to detect differences in microvascular function after 6 months of Lovaza® and differences in ethnic responses.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months. |
|
| omega-3-ethyl esters 4g | Active Comparator | Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| omega-3-ethyl esters | Drug | Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (>500 mg/dL) triglyceride (TG) levels in adult patients. |
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Conduction Amplitude. | 19 participants in each arm( placebo or omega-3-ethyl esters 4g) were analyzed . Conduction velocities and amplitude of the following nerves were compared between each arm: Tibial Nerve Ankle Amplitude, Tibial Nerve Popliteal Amplitude, Median Nerve Wrist Amplitude, Median Nerve Elbow Amplitude, Peroneal Motor Nerve Ankle Amplitude, Peroneal Motor Nerve Below Fibular Amplitude, Peroneal Motor Nerve Above Fibular Amplitude, Sensory Median Nerve Wrist Amplitude, Sensory Ulnar, Sensory Sural Ankle Ampltiude Wrist Ampltiude | One year |
| Measurements of Indices of Large and Small Fiber Nerve Function Including Heart Rate Variation Measures. | Quantitative Autonomic Function Tests (QAFTs) were performed. Primarily, power spectral analysis of heart rate variability (HRV) and time- and frequency-domain analyses, including measures of the sympathetic and parasympathetic control of the heart beat (R-R interval), were recorded with deep breathing, Valsalva, and standing from the sitting position maneuvers. Additionally, the sample difference of the beat to beat (NN) intervals and the TSP was calculated as well as the standard deviation of all normal R-R intervals (sdNN). | One year |
| Measurements of Indices of Large and Small Fiber Nerve Function Using Vibration and Thermal Thresholds. | Quantitative Sensory Tests (QSTs), including, cold sensation threshold, cold pain threshold and vibration detection threshold, were used to evaluate peripheral sensory perception. | One year |
| Percent Change in Measurements of Indices of Large and Small Fiber Nerve Function Including Vibration Thresholds | Quantitative Sensory Tests (QSTs), including vibration detection threshold, were used to evaluate peripheral sensory perception. Mean represents percent change of total group. Measurements taken at baseline and at one year. | One year |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Aaron I Vinik, MD, PhD | Eastern Virginia Medical School | Principal Investigator |
| Henri K Parson, PhD | Eastern Virgina Medical School | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Strelitz Diabetes Center | Norfolk | Virginia | 23510 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Placebo | Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months. Placebo: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months. |
| FG001 | Lovaza | Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months. omega-3-acie ethyl esters: Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (>500 mg/dL) triglyceride (TG) levels in adult patients. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
The study was powered at 0.80 for a two-tail analysis with a sensitivity of a 30% delta in blood flow in 40 subjects. The standard deviation of the measurements was calculated at 45% of the treatment group mean. This assessment of variance could accommodate for 9% attrition or data loss in the study. 44 patients will be recruited in total.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Placebo | Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months. Placebo: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Conduction Amplitude. | 19 participants in each arm( placebo or omega-3-ethyl esters 4g) were analyzed . Conduction velocities and amplitude of the following nerves were compared between each arm: Tibial Nerve Ankle Amplitude, Tibial Nerve Popliteal Amplitude, Median Nerve Wrist Amplitude, Median Nerve Elbow Amplitude, Peroneal Motor Nerve Ankle Amplitude, Peroneal Motor Nerve Below Fibular Amplitude, Peroneal Motor Nerve Above Fibular Amplitude, Sensory Median Nerve Wrist Amplitude, Sensory Ulnar, Sensory Sural Ankle Ampltiude Wrist Ampltiude | Posted | Mean | Standard Error | uV | One year |
|
All adverse event data was collected per individual from time of consent to 6 months after consent.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo | Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months. Placebo: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Atypical Chest Pain | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment | Normal EKG, no evidence of myocardial infarction, normal stress test and echocardiogram and troponin normal |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Upper Respiratory Infection | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment | Patient administered 5-day Z-pack; all symptoms subsided |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Henri Parson | Eastern Virginia Medical School | (757)446-7976 | parsonhk@evms.edu |
Not provided
| ID | Term |
|---|---|
| D015228 | Hypertriglyceridemia |
| D003929 | Diabetic Neuropathies |
| ID | Term |
|---|---|
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C405603 | Omacor |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Drug | Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months. |
|
| Measurements of Indices of Large and Small Fiber Nerve Function Including Markers of Inflammation and Oxidative Stress. | Oxidative stress/inflammatory markers (IL1β, IKKβ, TLR4, TNF-α, JNK1, toll-like receptor 2) were assessed through a meal challenge. | One year |
| Efficacy Measures Are Nerve Conduction Studies; Specifically, Increases in Conduction Velocity. | One Year |
| Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Latency. | One Year |
| Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in F-wave Conduction | One Year |
| Efficacy Measures Examining Increased Vascular Response to Ischemic Block and to Local Warming at the Dorsum of the Foot. | One Year |
| BG001 | Lovaza | Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months. omega-3-acie ethyl esters: Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (>500 mg/dL) triglyceride (TG) levels in adult patients. |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Weight (lbs) | Mean | Standard Deviation | lbs |
|
| BMI kg/m^2 | Mean | Standard Deviation | kg/m^2 |
|
| Qualifying triglyceride level (mg/dL) | Mean | Standard Deviation | mg/dL |
|
| Total cholesterol (mg/dL) | Mean | Standard Deviation | (mg/dL) |
|
| HDL cholesterol (mg/dL) | Mean | Standard Deviation | (mg/dL) |
|
| LDL cholesterol (mg/dL) | Mean | Standard Deviation | (mg/dL) |
|
| HbA1c (%) | Mean | Standard Deviation | % |
|
| Fasting glucose (mg/dL) | Mean | Standard Deviation | (mg/dL) |
|
| serum glutamate oxaloacetate transaminase(AST) (u/L) | Mean | Standard Deviation | (u/L) |
|
| serum glutamate pyruvate transaminase (ALT) (u/L) | Mean | Standard Deviation | (u/L) |
|
| Alkaline phosphatase (u/L) | Mean | Standard Deviation | (u/L) |
|
| C-peptide (ng/mL) | Mean | Standard Deviation | (ng/mL) |
|
| Insulin (uIU/mL) | Mean | Standard Deviation | (uIU/mL) |
|
| OG001 | Omega-3-ethyl Esters 4g | Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months. omega-3-ethyl esters: Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (>500 mg/dL) triglyceride (TG) levels in adult patients. |
|
|
| Primary | Measurements of Indices of Large and Small Fiber Nerve Function Including Heart Rate Variation Measures. | Quantitative Autonomic Function Tests (QAFTs) were performed. Primarily, power spectral analysis of heart rate variability (HRV) and time- and frequency-domain analyses, including measures of the sympathetic and parasympathetic control of the heart beat (R-R interval), were recorded with deep breathing, Valsalva, and standing from the sitting position maneuvers. Additionally, the sample difference of the beat to beat (NN) intervals and the TSP was calculated as well as the standard deviation of all normal R-R intervals (sdNN). | Posted | Mean | Standard Error | ms | One year |
|
|
|
| Primary | Measurements of Indices of Large and Small Fiber Nerve Function Using Vibration and Thermal Thresholds. | Quantitative Sensory Tests (QSTs), including, cold sensation threshold, cold pain threshold and vibration detection threshold, were used to evaluate peripheral sensory perception. | Posted | Mean | Standard Error | °C | One year |
|
|
|
| Primary | Percent Change in Measurements of Indices of Large and Small Fiber Nerve Function Including Vibration Thresholds | Quantitative Sensory Tests (QSTs), including vibration detection threshold, were used to evaluate peripheral sensory perception. Mean represents percent change of total group. Measurements taken at baseline and at one year. | Posted | Mean | Standard Error | % Change | One year |
|
|
|
| Primary | Measurements of Indices of Large and Small Fiber Nerve Function Including Markers of Inflammation and Oxidative Stress. | Oxidative stress/inflammatory markers (IL1β, IKKβ, TLR4, TNF-α, JNK1, toll-like receptor 2) were assessed through a meal challenge. | Posted | Mean | Standard Error | pg/ml | One year |
|
|
|
| Primary | Efficacy Measures Are Nerve Conduction Studies; Specifically, Increases in Conduction Velocity. | Posted | Mean | Standard Error | m/s | One Year |
|
|
|
| Primary | Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Latency. | Posted | Mean | Standard Error | ms | One Year |
|
|
|
| Primary | Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in F-wave Conduction | Posted | Mean | Standard Error | m/s | One Year |
|
|
|
| Primary | Efficacy Measures Examining Increased Vascular Response to Ischemic Block and to Local Warming at the Dorsum of the Foot. | Measures of vascular response to ischemic block and local warming at the dorsum of the foot were not reliably collected for this assessment due to the difficulty of analysis and the inability to properly distinguish a vascular response in patients. | Posted | One Year |
|
|
| 4 |
| 19 |
| 7 |
| 19 |
| EG001 | Lovaza | Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months. omega-3-acie ethyl esters: Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (>500 mg/dL) triglyceride (TG) levels in adult patients. | 2 | 19 | 8 | 19 |
|
| Head trauma due to accidental fall | Injury, poisoning and procedural complications | Non-systematic Assessment | Patient fell and suffered bruises and cuts to her face; received more than 25 stitches and wound care to her face. Later, patient experienced vomiting and headaches and later received a CAT scan which displayed an internal head bleed due to trauma. |
|
| Hospitilization due to low blood pressure and fainting | Cardiac disorders | Non-systematic Assessment | Patient passed out in home, ER recorded BP as 63/48. During ER stay, patient had an EKG, MRI, ultrasound, and carotid doppler tests which all proved to be normal. Cause of fainting undetermined. |
|
| Overnight stay in ER for observation after experiencing chest pain | Cardiac disorders | Non-systematic Assessment | Patient seen in ER after reporting feeling pain in chest that "radiated down her arm" and some pain in her back and abdomen. A nuclear stress test was performed and patient states that no blockages were found. |
|
| Planned surgery to treat Achalasia/Esophageal motility disorder | Surgical and medical procedures | Non-systematic Assessment | Patient underwent a planned surgical procedure to treat Achalasia/Esophageal motility disorder. Procedure lasted 6 hours, and patient was under anesthesia for 7 hours. This was an in-patient procedure. |
|
| Emergency Surgery to relieve bile duct obstruction | Surgical and medical procedures | Non-systematic Assessment | Patient went to ER reporting abdominal pain, losing 6 pounds, dark urine and clay-colored stool.CT scan found 2 stones in gallbladder - 1 occluding the common bile duct. An Endoscopic Retrograde Cholangiopancreatography removed both offending stones. |
|
|
| Severe-Moderate Diarrhea | Gastrointestinal disorders | Non-systematic Assessment | Patient experienced severe to moderate diarrhea which was explained as "uncontrollable" at times |
|
| Dehyrdation/Severe Vomiting/Diarrhea | Gastrointestinal disorders | Non-systematic Assessment | Patient went to ER for severe dehydration (administered 2 IV bags) and nausea (given Zofran). Patient went back to ER two weeks later for similar symptoms. Dehydration most likely due to vomiting and severe diarrhea |
|
| Personal Injury | Injury, poisoning and procedural complications | Non-systematic Assessment | Patient slipped in shower and struck right elbow against the shower wall. Patient seen at ER, where x-rays revealed no abnormalities. |
|
| Dizziness/Fainting | Nervous system disorders | Non-systematic Assessment | While stopped at red light, patient reports feeling dizzy and then fainting causing her to strike another car. Bloodwork/CT done at ER with normal results. Cause of fainting undetermined. |
|
| Fainting/Dizziness | Nervous system disorders | Non-systematic Assessment | While exiting a vehicle, patient reports fainting (no dizziness reported). Cause of fainting unknown. |
|
| Eye Discharge | Eye disorders | Non-systematic Assessment | Patient reports experiencing significant increases in eye discharge. Patient reports seeing an ophthalmologist with no significant abnormalities noted. |
|
| Cranial/Facial Lesions | Skin and subcutaneous tissue disorders | Non-systematic Assessment | Patients reports sores on scalp and unhealing dark spots on facial skin. Patients also reports "stabbing" pain in left knee and left side of foot. |
|
| Abdominal Pain | Gastrointestinal disorders | Non-systematic Assessment | Patient reports experiencing lower left quadrant pain with increased night sweats and low-grade fever. Patient seen at ER, where CAT scan revealed swollen lymph nodes in the small mesenteric bowel. |
|
| Bacterial Infection | Infections and infestations | Non-systematic Assessment | Patient reports a bacterial infection and rash on abdomen and chest. Seen at dermatologist and prescribed prescription body wash, Z-pack, and skin culture. |
|
| Personal Injury | Injury, poisoning and procedural complications | Non-systematic Assessment | Rising from a seated position, patient fell. No dizziness, shortness of breath, or blurred vision noted. Patient did not receive any further medical attention. |
|
| Bladder Suspension with Sling | Surgical and medical procedures | Non-systematic Assessment | Patient underwent cystoscopy with transobturator sling. Not considered an emergency surgery. |
|
| Bronchitis | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment | Patient suffered asthma-related bronchitis; prescribed prednisone, antibiotic, and inhaler. |
|
| Upper limb weakness | Musculoskeletal and connective tissue disorders | Non-systematic Assessment | Patient reports increased arm pain/weakness bilaterally. Ordered nerve conduction study on median, ulnar, and radial nerves bilaterally resulting in otherwise normal results. |
|
| Dry/Achy Eyes | Eye disorders | Non-systematic Assessment | Patient reports experiencing increased eye strain and very dry eyes. Patient seen at ophthalmologist; prescribed artificial tears to be take Q 4 hours. |
|
| Bells Palsy | Nervous system disorders | Non-systematic Assessment | During routine physical, patient showed signs and symptoms of having Bells Palsy. Patient also reports being recently diagnosed with genital herpes. Patient prescribed metrozol pack and valtrex. |
|
| Back Pain | Musculoskeletal and connective tissue disorders | Non-systematic Assessment | Patient reports experiencing increased lower back pain. Went to ER, where x-rays revealed no significant findings. Pain attributed to soft tissue injury due to overactivity or arthritis. Received two shots of Dilaudid. |
|
| Hyperglycemia | Endocrine disorders | Non-systematic Assessment | Patients reports consistent higher than normal blood glucose levels. Patient instructed to continue to monitor levels. |
|
Not provided
Not provided
| D009750 |
| Nutritional and Metabolic Diseases |
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D048909 | Diabetes Complications |
| D003920 | Diabetes Mellitus |
| D004700 | Endocrine System Diseases |
| Deep Breathing sdNN (ms) |
|
| Deep Breathing rmsSD (ms) |
|
| Valsalva sdNN (ms) |
|
| Valsalva rmsSD (ms) |
|
| Standing sdNN (ms) |
|
| Standing rmsSD (ms) |
|
| Cold Sesnation Threshold-Toe (°C) |
|
| Cold Pain Threshold-Toe (°C) |
|
| Cold Sensation Threshold-Dorsum (°C) |
|
| Cold Pain Threshold-Dorsum (°C) |
|
| TLR4 (pg/ml) |
|
| TNFα (pg/ml) |
|
| JNK1 (pg/ml) |
|
| toll-like receptor 2 (pg/ml) |
|
| Peroneal Motor Nerve Bel. Fib. Conduction Velocity |
|
| Peroneal Motor Nerve Abo. Fib. Conduction Velocity |
|
| Sensory Median Nerve Wrist Conduction Velocity |
|
| Sensory Ulnar Wrist Conduction Velocity |
|
| Sensory Sural Ankle Conduction Velocity |
|
| Median Nerve Wrist Latency |
|
| Median Nerve Elbow Latency |
|
| Peroneal Motor Nerve Ankle Latency |
|
| Peroneal Motor Nerve Below Fibular Latency |
|
| Peroneal Motor Nerve Above Fibular Latency |
|
| Sensory Median Nerve Wrist Latency |
|
| Sensory Ulnar Wrist Latency |
|
| Sensory Sural Ankle Latency |
|
| Peroneal Motor Nerve F-Wave Conduction |
|